Estrella Immunopharma reports on May 22 after a brutal month for the stock — and the setup heading in is one of persistent price weakness against a borrow market that has quietly loosened.
The price tells the clearest story. ESLA has fallen 35% over the past month to $1.11, with losses of nearly 12% in the past week alone and 8% in the final session before this preview. Peers have been mixed: TOVX dropped 18% on the week and CVM shed 16%, while SPRO managed a nearly 9% gain — suggesting the weakness in ESLA reflects both sector headwinds and stock-specific pressure rather than a pure biotech selloff.
Short interest itself is not the story here. It is running at just 0.34% of the float — a trivially small figure for a micro-cap biotech — though the week-on-week count has risen more than 50%. That week-on-week jump looks dramatic but amounts to a very small absolute number of shares. Borrow costs remain elevated at roughly 15.7% annualised, down sharply from 40% in early April as the short position has unwound. Availability is now exceptionally loose at 7,440% — meaning shares to borrow vastly outnumber current short interest — so there is no squeeze dynamic in the lending market.
The only analyst coverage comes from D. Boral Capital, which maintained its Buy rating and an $8 target back in February — a figure still well above the current price at $1.11, though that target was cut from $16 in January. The bull case rests on the ARTEMIS T-cell platform targeting CD19 and CD22, which recently enrolled its first Phase II patient, and an $8M financing completed earlier this year. Bears point to a tiny clinical dataset, heavy competition in the CAR-T space, and a valuation that hinges almost entirely on EB103 succeeding in trials — a programme the analyst ascribes just a 30% probability of success.
Historical reactions offer limited comfort for bulls. ESLA has fallen on the day of every one of its last four earnings events — by as much as 13% in one case — before recovering in some instances. The five-day reaction has been deeply negative on two of those four occasions. Thursday's print will test whether the Phase II progression update is enough to arrest a stock that has lost more than a third of its value in a single month.
See the live data behind this article on ORTEX.
Open ESLA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
